Treat‐and‐extend versus every‐other‐month regimens with aflibercept in age‐related macular degeneration

Abstract

Treat-and-extend (TAE) regimen with aflibercept improved the BCVA and CRT to the same extent as 2M regimen, with a reduced number of injections.